Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,872 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05358548RecruitingPhase 2
Alternating treatment for advanced lung and head-neck cancers
This Phase 2 study tests an approach that alternates treatments for advanced lung cancer or recurrent/metastatic head and neck squamous cell cancer. It may help by improving how well the cancer responds while managing side effects differently than standard back-to-back therapy.
Elizabeth, New JerseyAges 18 years+ - NCT05370144Recruiting
Pre-surgery chemotherapy and radiation for esophagus cancer
This study tests a new pre-surgery treatment plan that combines chemotherapy with focused, shorter-course radiation for esophagus or stomach-where-it-meets-the-esophagus (GEJ) adenocarcinoma. The goal is to shrink the tumor before surgery and improve treatment outcomes.
Calgary, AlbertaAges 18–80 - NCT05371132RecruitingPhase 1
PET scan study to track immune response after SBRT
This early (Phase 1) study uses a special PET scan to measure how your immune system responds after stereotactic body radiation therapy (SBRT). The goal is to see whether the scan result can serve as a marker of immune response, which may help future treatment planning.
Duarte, CaliforniaAges 18 years+ - NCT05378334Recruiting
Test herbal treatment for lung cancer spread to bone
This trial studies whether the herbal medicine HGXJT can improve outcomes and safety for people with non-small cell lung cancer that has spread to the bones. It is designed for a specific lung cancer type (EGFR and ALK wild type) and people who have not had certain immune treatments before.
Guangzhou, GuangdongAges 18–75 - NCT05384873Recruiting
Immunonutrition to improve immunotherapy in metastatic lung cancer
This trial studies whether adding special nutrition (oral immunonutrition supplements) can help immunotherapy work better in people with metastatic non-small cell lung cancer. Participants receive immunotherapy, with or without chemotherapy, and must be able to take oral supplements.
PaviaAges 18 years+ - NCT05388773RecruitingPhase 2
Surgery then lower-dose radiation for p16+ throat cancer
This Phase 2 study tests whether removing the tumor through the mouth, followed by a reduced course of radiation, can control HPV-related (p16+) oropharynx throat cancer. It may help reduce treatment intensity after surgery, while still aiming to keep the cancer from coming back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05394337RecruitingPhase 1/Phase 2
Immunotherapy before bladder surgery for cisplatin-ineligible patients
This trial tests two immunotherapy drugs given before bladder/urinary tract cancer surgery. It aims to shrink the tumor and improve outcomes in people who cannot safely take cisplatin chemotherapy.
Houston, TexasAges 18 years+ - NCT05413850RecruitingPhase 1/Phase 2
Lu-177 PSMA drug study for advanced prostate cancer
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
Miami, FloridaAges 18 years+ - NCT05419076RecruitingPhase 2
SRS radiation for small cell lung cancer with brain spread
This Phase 2 trial tests a type of focused radiation (stereotactic radiosurgery, or SRS) for people with small cell lung cancer that has spread to the brain. It looks at whether this approach can treat brain metastases when the cancer has limited to a certain number of spots.
Basking Ridge, New JerseyAges 18 years+ - NCT05421650Recruiting
Surgery to remove pelvic lymph node spread in cervical cancer
This trial studies whether surgically removing cancerous pelvic or nearby lymph nodes before or as part of standard treatment improves outcomes for women with certain cervical cancers. It focuses on people whose scans suggest lymph node metastasis can be safely removed.
BengaluruAges 20–70 - NCT05423262RecruitingPhase 1/Phase 2
TRK-950 for advanced solid tumors that standard treatment can’t control
This trial tests TRK-950 in people with advanced (locally advanced or metastatic) solid tumors when standard treatments have stopped working or aren’t available. It may help by trying a new treatment approach when current options are limited.
Nagoya, Aichi-kenAges 18 years+ - NCT05422911RecruitingPhase 2
Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Los Angeles, CaliforniaAges 18 years+ - NCT05430009RecruitingPhase 1
Radiation to liver plus immunotherapy for metastatic lung cancer
This Phase 1 study tests whether targeted radiation to liver tumors combined with immunotherapy can control metastatic non-small cell lung cancer. It aims to find a safe and effective treatment approach for people whose cancer has spread to the liver.
Ann Arbor, MichiganAges 18 years+ - NCT05443087Recruiting
Checking blood levels of targeted drugs for digestive cancers
This trial monitors how your prescribed targeted cancer medicine moves through your body by doing extra blood tests. The goal is to understand the drug’s levels and dosing in people with advanced digestive cancers, so treatment can be better managed.
AmiensAges 18 years+ - NCT05455619RecruitingPhase 1/Phase 2
Targeted drugs for PI3K-altered, HR+/HER2- breast cancer
This Phase 1/2 trial tests how well a combination of targeted medicines works for advanced or returning HR+/HER2- breast cancer that has a PI3K pathway change (such as PIK3CA, PTEN, or AKT1). It may help by blocking growth signals in the cancer and is especially for people whose cancer has progressed after hormone therapy and a CDK4/6 inhibitor.
Loma Linda, CaliforniaAges 18 years+ - NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT05477576RecruitingPhase 3
Lu-177–treated NET patients: new drug versus standard care
This Phase 3 trial tests RYZ101 versus standard of care in people with inoperable, well-differentiated SSTR-positive GI or pancreas neuroendocrine tumors (NETs) that keep growing after Lu-177 SSA. It may help by improving tumor control after your prior targeted radiation treatment.
Phoenix, ArizonaAges 18 years+ - NCT05480644Recruiting
Blood biomarker study for brain tumor patients
This study collects blood (and looks at samples) from adults who have a confirmed brain tumor, either one that started in the brain or one that spread to the brain. The goal is to understand biomarkers—signals in the body—that may help improve diagnosis or tracking over time.
Durham, North CarolinaAges 18 years+ - NCT05488548RecruitingPhase 1
Study drug that blocks BET and CBP/p300 in advanced cancers
This Phase 1 trial tests an investigational medicine that targets BET and CBP/p300 to try to slow or control advanced, hard-to-treat cancers. You may be eligible if you have certain prostate cancer or NUT midline carcinoma, or specific blood cancers like CMML or myelofibrosis (MF), and your body functions are strong enough for chemotherapy-style treatment.
Phoenix, ArizonaAges 18 years+ - NCT05490472RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors that stopped responding
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
Detroit, MichiganAges 18 years+ - NCT05494060RecruitingPhase 2
Adjuvant chemo plus immunotherapy for ctDNA-positive stomach cancer
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
Nanjing, JiangsuAges 18–75 - NCT05494190Recruiting
Treatment strategy for lymph node spread in hypopharyngeal cancer
This trial studies treatment choices for people with hypopharyngeal squamous cell cancer that has spread to certain neck lymph nodes. The goal is to help control the cancer in the neck and improve outcomes when the lymph node area can be surgically managed.
Harbin, HeilongjiangAges 18–75 - NCT05495152RecruitingPhase 3
Sintilimab after esophageal surgery to help prevent cancer return
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
Zhengzhou, HenanAges 18–70 - NCT05498064Recruiting
Study of ensartinib for advanced ALK-positive lung cancer
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,872 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.